Literature DB >> 25348792

Haematological cancer: Optimizing the treatment of multiple myeloma.

Gareth J Morgan1, Frits van Rhee1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25348792     DOI： 10.1038/nrclinonc.2014.185

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  The future of autologous stem cell transplantation in myeloma.

Authors:  Frits van Rhee; Sergio Giralt; Bart Barlogie
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

2.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

3.  Autologous transplantation and maintenance therapy in multiple myeloma.

Authors:  Antonio Palumbo; Federica Cavallo; Francesca Gay; Francesco Di Raimondo; Dina Ben Yehuda; Maria Teresa Petrucci; Sara Pezzatti; Tommaso Caravita; Chiara Cerrato; Elena Ribakovsky; Mariella Genuardi; Anna Cafro; Magda Marcatti; Lucio Catalano; Massimo Offidani; Angelo Michele Carella; Elena Zamagni; Francesca Patriarca; Pellegrino Musto; Andrea Evangelista; Giovannino Ciccone; Paola Omedé; Claudia Crippa; Paolo Corradini; Arnon Nagler; Mario Boccadoro; Michele Cavo
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

4.  Curing myeloma at last: defining criteria and providing the evidence.

Authors:  Bart Barlogie; Alan Mitchell; Frits van Rhee; Joshua Epstein; Gareth J Morgan; John Crowley
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

5.  Approach to the treatment of multiple myeloma: a clash of philosophies.

Authors:  S Vincent Rajkumar; Gösta Gahrton; P Leif Bergsagel
Journal:  Blood       Date:  2011-07-25       Impact factor: 22.113

6.  Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.

Authors:  E Fritz; H Ludwig
Journal:  Ann Oncol       Date:  2000-11       Impact factor: 32.976

7.  Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Authors:  Sagar Lonial; Ravi Vij; Jean-Luc Harousseau; Thierry Facon; Philippe Moreau; Amitabha Mazumder; Jonathan L Kaufman; Xavier Leleu; L Claire Tsao; Christopher Westland; Anil K Singhal; Sundar Jagannath
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

8.  The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

Authors:  Gareth J Morgan; Walter M Gregory; Faith E Davies; Sue E Bell; Alexander J Szubert; Julia M Brown; Nuria N Coy; Gordon Cook; Nigel H Russell; Claudius Rudin; Huw Roddie; Mark T Drayson; Roger G Owen; Fiona M Ross; Graham H Jackson; J Anthony Child
Journal:  Blood       Date:  2011-10-20       Impact factor: 22.113

9.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Authors:  J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby
Journal:  N Engl J Med       Date:  2003-05-08       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.